ClinicalTrials.gg
CompletedNCT02558894Updated Aug 2, 2018Results posted

Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

A Phase 2 interventional study of MEDI4736 monotherapy and tremelimumab+MEDI4736 in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Read the detailed description

This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B.

02

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma

Keywords

  • Pancreatic Ductal Adenocarcinoma, PDAC
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

  1. or cytologically confirmed PDAC, no more than 1 prior chemotherapy regimen
  2. 0 or 1
  3. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) scan and that is suitable for accurate repeated measurements

Exclusion Criteria:

  1. Any concurrent chemotherapy, product , biologic, or hormonal therapy for cancer treatment.
  2. History of
  3. Ascites requiring intervention
  4. or spinal cord compression.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    MEDI4736 monotherapy

    MEDI4736 via IV infusion.

    Drug: MEDI4736 monotherapy

  • Experimental
    tremelimumab+MEDI4736

    MEDI4736+tremelimumab via IV infusion.

    Drug: tremelimumab+MEDI4736

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit and not less than 4 weeks after the visit when response was first observed with no evidence of progression between the initial and CR/PR confirmation visits. Results are reported as percentage of patients with a confirmed response and percentage of patients with confirmed or unconfirmed responses (i.e., including single visit responses).

    Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

Secondary outcomes

  1. Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1

    PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. Results are reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.

    Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

  2. PFS Rate at 3 Months and at 6 Months

    PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. PFS rates were calculated using Kaplan-Meier estimates of the cumulative probability of PFS. The PFS rate at 3 months and 6 months was equivalent to the percentage of patients with PFS after 3 months and 6 months, respectively.

    Time frame: From date of first infusion until confirmed disease progression or death (up to 3 months and 6 months)

  3. Overall Survival (OS)

    OS was defined as the time from the date of randomisation until death due to any cause. Results are reported as median OS, calculated using the Kaplan-Meier technique.

    Time frame: From date of first infusion until death (up to approximately 18 months for the data analysis cut-off)

  4. Survival Status, Presented as OS Rate, at 6 Months and at 12 Months

    OS was defined as the time from the date of randomisation until death due to any cause. OS rates were calculated using Kaplan-Meier estimates of the cumulative probability of survival at each indicated time period. The OS rate at 6 months and 12 months was equivalent to the percentage of patients with OS after 6 months and 12 months, respectively.

    Time frame: From date of first infusion until death (up to 6 months and 12 months)

  5. Best Objective Response (BoR) Using Investigator Assessments According to RECIST 1.1

    BoR was calculated based on the overall visit responses from each RECIST assessment. It was the best response a patient had following date of first dosing but prior to starting any subsequent cancer therapy and prior to RECIST progression or last evaluable assessment in absence of RECIST progression. Categorisation of BoR was based on RECIST using the following response categories: CR and PR for status of 'Response'; Stable Disease (SD) ≥6 weeks, Progressive Disease (PD) and Not Evaluable (NE) for status of 'Non-response'. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of diameters of TLs taking as reference the smallest sum on study. NE was only relevant if any of the TLs were not assessed or not evaluable or had a lesion intervention at this visit. Results are reported as number of patients with BoR for each of the indicated categories.

    Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)

  6. Disease Control Rate (DCR) Using Investigator Assessments According to RECIST 1.1

    DCR at 3 months was defined as the percentage of patients who have a BoR of CR or PR in the first 3 months or who have demonstrated SD for a minimum interval of 13 weeks following the start of treatment. DCR at 6 months was defined as the percentage of patients who have a BoR of CR or PR in the first 6 months or who have demonstrated SD for a minimum interval of 26 weeks following the start of treatment. DCR at 12 months was defined as the percentage of patients who have a BoR of CR or PR in the first 12 months or who have demonstrated SD for a minimum interval of 52 weeks following the start of treatment. Results are reported as the percentage of patients with disease control for each of the indicated categories.

    Time frame: From date of first infusion until confirmed disease progression or death (up to 3 months, 6 months and 12 months)

  7. Pharmacokinetics (PK) of Durvalumab (MEDI4736)

    To evaluate PK, blood samples were collected pre- and post-dose and durvalumab (MEDI4736) concentrations in serum were determined. On Day 1 of Cycles 1, 4 and 7 (Weeks 0, 12 and 24), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of durvalumab and within 10 minutes of end of infusion of tremelimumab \[for patients receiving durvalumab plus tremelimumab\]). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for durvalumab was relative to the respective last dose. Results are reported as mean pre- or post-dose durvalumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.

    Time frame: Blood samples were collected pre-dose on Day 1 (Week 0), Week 4, Week 12 and Week 24, post-dose on Day 1, Week 12 and Week 24, and additionally at 3 months after the last dose (follow-up).

  8. PK of Tremelimumab

    To evaluate PK, blood samples were collected pre- and post-dose and tremelimumab concentrations in serum were determined. On Day 1 of Cycles 1 and 4 (Weeks 0 and 12), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of tremelimumab). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for tremelimumab was relative to the respective last dose. Results are reported as mean pre- or post-dose tremelimumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.

    Time frame: Blood samples were collected pre-dose on Day 1 (Week 0), Week 4 and Week 12, post-dose on Day 1 and Week 12, and additionally at 3 months after the last dose (follow-up).

  9. Presence of Antidrug Antibodies (ADAs) for Durvalumab (MEDI4736)

    ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti-durvalumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.

    Time frame: Immunogenicity samples were collected on Day 1 (Week 0), Week 4, Week 12 and Week 24, and additionally at 3 months and 6 months after the last dose (follow-up).

  10. Presence of ADAs for Tremelimumab

    ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti- tremelimumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.

    Time frame: Immunogenicity samples were collected on Day 1 (Week 0), Week 4 and Week 12, and additionally at 3 months and 6 months after the last dose (follow-up).

07

Results

Posted Aug 2, 2018
Limitations and caveats
Study consisted of Part A Lead-in and 2 possible options for Part B: non-randomised expansion or randomised controlled trial. Criteria to open either option for Part B were not met and study was closed prematurely. Only Part A was conducted.

Participant flow

First patient enrolled: 16 Nov 2015; Part A data cut-off: 26 May 2017. The study contained a Part B which was not opened; only Part A was conducted. Study assessed efficacy of durvalumab (MEDI4736) + tremelimumab combination therapy compared to durvalumab (MEDI4736) monotherapy. Study performed at 21 sites in 6 countries.

Participant flow — Overall Study
MilestoneDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Started3233
Patients who received ip3232
Completed00
Not completed3233
Withdrew: Death; any cause, entire study duration2831
Withdrew: Withdrawal by subject21
Withdrew: Closure of part a21

Outcome measures

PrimaryObjective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit and not less than 4 weeks after the visit when response was first observed with no evidence of progression between the initial and CR/PR confirmation visits. Results are reported as percentage of patients with a confirmed response and percentage of patients with confirmed or unconfirmed responses (i.e., including single visit responses).

Time frame:
From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of participantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Confirmed responses only3.1 (0.08 to 16.22)0 (0 to 10.58)
Confirmed and unconfirmed responses3.1 (0.08 to 16.22)6.1 (0.74 to 20.23)
SecondaryProgression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1

PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. Results are reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.

Time frame:
From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
Reported as:
Median · Months
Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1
MonthsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.11.5 (1.2 to 1.5)1.5 (1.3 to 1.5)
SecondaryPFS Rate at 3 Months and at 6 Months

PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. PFS rates were calculated using Kaplan-Meier estimates of the cumulative probability of PFS. The PFS rate at 3 months and 6 months was equivalent to the percentage of patients with PFS after 3 months and 6 months, respectively.

Time frame:
From date of first infusion until confirmed disease progression or death (up to 3 months and 6 months)
Reported as:
Number · Percentage of participants
PFS Rate at 3 Months and at 6 Months
Percentage of participantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
PFS rate at 3 months9.4 (2.4 to 22.3)10.9 (3.0 to 24.7)
PFS rate at 6 months9.4 (2.4 to 22.3)3.6 (0.3 to 15.4)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomisation until death due to any cause. Results are reported as median OS, calculated using the Kaplan-Meier technique.

Time frame:
From date of first infusion until death (up to approximately 18 months for the data analysis cut-off)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Overall Survival (OS)3.1 (2.2 to 6.1)3.6 (2.7 to 6.1)
SecondarySurvival Status, Presented as OS Rate, at 6 Months and at 12 Months

OS was defined as the time from the date of randomisation until death due to any cause. OS rates were calculated using Kaplan-Meier estimates of the cumulative probability of survival at each indicated time period. The OS rate at 6 months and 12 months was equivalent to the percentage of patients with OS after 6 months and 12 months, respectively.

Time frame:
From date of first infusion until death (up to 6 months and 12 months)
Reported as:
Number · Percentage of participants
Survival Status, Presented as OS Rate, at 6 Months and at 12 Months
Percentage of participantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Survival rate at 6 months36.2 (20.0 to 52.7)34.9 (19.2 to 51.1)
Survival rate at 12 months8.8 (1.8 to 22.8)6.3 (1.1 to 18.4)
SecondaryBest Objective Response (BoR) Using Investigator Assessments According to RECIST 1.1

BoR was calculated based on the overall visit responses from each RECIST assessment. It was the best response a patient had following date of first dosing but prior to starting any subsequent cancer therapy and prior to RECIST progression or last evaluable assessment in absence of RECIST progression. Categorisation of BoR was based on RECIST using the following response categories: CR and PR for status of 'Response'; Stable Disease (SD) ≥6 weeks, Progressive Disease (PD) and Not Evaluable (NE) for status of 'Non-response'. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of diameters of TLs taking as reference the smallest sum on study. NE was only relevant if any of the TLs were not assessed or not evaluable or had a lesion intervention at this visit. Results are reported as number of patients with BoR for each of the indicated categories.

Time frame:
From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
Reported as:
Count of participants · Participants
Best Objective Response (BoR) Using Investigator Assessments According to RECIST 1.1
ParticipantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Response: Total10
Response: CR00
Response: PR10
Non-response: Total3133
Non-response: Stable disease ≥6 weeks57
Non-response: Progression of disease2625
Non-response: Not evaluable01
SecondaryDisease Control Rate (DCR) Using Investigator Assessments According to RECIST 1.1

DCR at 3 months was defined as the percentage of patients who have a BoR of CR or PR in the first 3 months or who have demonstrated SD for a minimum interval of 13 weeks following the start of treatment. DCR at 6 months was defined as the percentage of patients who have a BoR of CR or PR in the first 6 months or who have demonstrated SD for a minimum interval of 26 weeks following the start of treatment. DCR at 12 months was defined as the percentage of patients who have a BoR of CR or PR in the first 12 months or who have demonstrated SD for a minimum interval of 52 weeks following the start of treatment. Results are reported as the percentage of patients with disease control for each of the indicated categories.

Time frame:
From date of first infusion until confirmed disease progression or death (up to 3 months, 6 months and 12 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Using Investigator Assessments According to RECIST 1.1
Percentage of participantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
At 3 months9.4 (1.98 to 25.02)6.1 (0.74 to 20.23)
At 6 months6.3 (0.77 to 20.81)0 (0.00 to 10.58)
At 12 months3.1 (0.08 to 16.22)0 (0.00 to 10.58)
SecondaryPharmacokinetics (PK) of Durvalumab (MEDI4736)

To evaluate PK, blood samples were collected pre- and post-dose and durvalumab (MEDI4736) concentrations in serum were determined. On Day 1 of Cycles 1, 4 and 7 (Weeks 0, 12 and 24), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of durvalumab and within 10 minutes of end of infusion of tremelimumab \[for patients receiving durvalumab plus tremelimumab\]). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for durvalumab was relative to the respective last dose. Results are reported as mean pre- or post-dose durvalumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.

Time frame:
Blood samples were collected pre-dose on Day 1 (Week 0), Week 4, Week 12 and Week 24, post-dose on Day 1, Week 12 and Week 24, and additionally at 3 months after the last dose (follow-up).
Reported as:
Mean · Micrograms per millilitre (mcg/mL)
Pharmacokinetics (PK) of Durvalumab (MEDI4736)
Micrograms per millilitre (mcg/mL)Durvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
Cycle 1, Day 1, pre-infusion (Day 1)217.338 ± 345.4913—
Cycle 1, Day 1, post-infusion (Day 1)566.078 ± 151.4199562.218 ± 152.3811
Cycle 2, Day 1, pre-infusion (Day 29)100.417 ± 39.722998.668 ± 36.5072
Cycle 4, Day 1, pre-infusion (Day 85)236.205 ± 98.8964228.450 ± 36.8395
Cycle 4, Day 1, post-infusion (Day 85)825.818 ± 322.8247760.456 ± 100.6974
Cycle 7, Day 1, pre-infusion (Day 169)166.736 ± 47.3872152.706 ± NA
Cycle 7, Day 1, post-infusion (Day169)918.270 ± 98.4286825.578 ± NA
3-month follow-up38.456 ± NA19.684 ± 20.2664
SecondaryPK of Tremelimumab

To evaluate PK, blood samples were collected pre- and post-dose and tremelimumab concentrations in serum were determined. On Day 1 of Cycles 1 and 4 (Weeks 0 and 12), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of tremelimumab). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for tremelimumab was relative to the respective last dose. Results are reported as mean pre- or post-dose tremelimumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.

Time frame:
Blood samples were collected pre-dose on Day 1 (Week 0), Week 4 and Week 12, post-dose on Day 1 and Week 12, and additionally at 3 months after the last dose (follow-up).
Reported as:
Mean · mcg/mL
PK of Tremelimumab
mcg/mLDurvalumab (MEDI4736) Plus Tremelimumab
Cycle 1, Day 1, pre-infusion (Day 1)13.114 ± 11.7182
Cycle 1, Day 1, post-infusion (Day 1)24.477 ± 6.3516
Cycle 2, Day 1, pre-infusion (Day 29)4.880 ± 2.2623
Cycle 4, Day 1, pre-infusion (Day 85)8.753 ± 4.9962
Cycle 4, Day 1, post-infusion (Day 85)21.150 ± 5.8997
SecondaryPresence of Antidrug Antibodies (ADAs) for Durvalumab (MEDI4736)

ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti-durvalumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.

Time frame:
Immunogenicity samples were collected on Day 1 (Week 0), Week 4, Week 12 and Week 24, and additionally at 3 months and 6 months after the last dose (follow-up).
Reported as:
Count of participants · Participants
Presence of Antidrug Antibodies (ADAs) for Durvalumab (MEDI4736)
ParticipantsDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
ADA prevalence15
ADA incidence03
ADA pos post-baseline and pos at baseline00
ADA pos post-baseline and not detected at baseline03
ADA not detected post-baseline and pos at baseline12
Treatment-boosted ADA00
Persistent positive03
Transient positive00
Never positive2419
SecondaryPresence of ADAs for Tremelimumab

ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti- tremelimumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.

Time frame:
Immunogenicity samples were collected on Day 1 (Week 0), Week 4 and Week 12, and additionally at 3 months and 6 months after the last dose (follow-up).
Reported as:
Count of participants · Participants
Presence of ADAs for Tremelimumab
ParticipantsDurvalumab (MEDI4736) Plus Tremelimumab
ADA prevalence2
ADA incidence0
ADA pos post-baseline and pos at baseline1
ADA pos post-baseline and not detected at baseline0
ADA not detected post-baseline and pos at baseline1
Treatment-boosted ADA0
Persistent positive0
Transient positive1
Never positive23

Adverse events

Collected over Treatment-emergent adverse event (TEAE) data is reported for the treatment period (up to 12 months) + follow-up (up to 90 days). Overall timeframe: up to approximately 15 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab (MEDI4736) Plus Tremelimumab19/32 (59.4%)11/32 (34.4%)26/32 (81.3%)
Durvalumab (MEDI4736) Monotherapy16/32 (50%)9/32 (28.1%)26/32 (81.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
DiarrhoeaGastrointestinal disorders3/320/32
AscitesGastrointestinal disorders2/321/32
PyrexiaGeneral disorders0/322/32
CholangitisHepatobiliary disorders2/320/32
Acute kidney injuryRenal and urinary disorders0/322/32
Abdominal distensionGastrointestinal disorders1/320/32
Gastrointestinal haemorrhageGastrointestinal disorders0/321/32
HaematemesisGastrointestinal disorders1/320/32
HaematocheziaGastrointestinal disorders0/321/32
Intestinal obstructionGastrointestinal disorders1/320/32
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDurvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) Monotherapy
FatigueGeneral disorders6/329/32
Decreased appetiteMetabolism and nutrition disorders8/328/32
ConstipationGastrointestinal disorders5/327/32
DyspepsiaGastrointestinal disorders6/322/32
PyrexiaGeneral disorders6/322/32
DiarrhoeaGastrointestinal disorders4/325/32
NauseaGastrointestinal disorders4/325/32
VomitingGastrointestinal disorders5/325/32
HypothyroidismEndocrine disorders4/320/32
AstheniaGeneral disorders3/324/32

Baseline characteristics

All patients in the FAS who were randomised to treatment were included in the baseline analysis.

Age, Continuous
Age, Continuous(Years)Durvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) MonotherapyTotal
Mean61.3 ± 9.6061.6 ± 9.5461.5 ± 9.49
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) MonotherapyTotal
Female171431
Male151934
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) MonotherapyTotal
Hispanic or Latino202
Not Hispanic or Latino303363
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab (MEDI4736) Plus TremelimumabDurvalumab (MEDI4736) MonotherapyTotal
American Indian or Alaska Native000
Asian151025
Native Hawaiian or Other Pacific Islander000
Black or African American000
White172239
More than one race000
Unknown or Not Reported011
08

Study locations

21 sites
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3T2, Canada
  • Research Site
    Friedrichshafen, 88045, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Tuebingen, 72076, Germany
  • Research Site
    Seongnam-si, 463-707, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Nijmegen, 6525 GA, Netherlands
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28034, Spain
09

References and documents

Publications

  • O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 1;5(10):1431-1438. doi: 10.1001/jamaoncol.2019.1588. PubMed 31318392 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Jun 2017, 18 months.

Results were first posted in Aug 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2015
First posted
Sep 24, 2015
StartActual
Nov 16, 2015
Primary completionActual
Jun 15, 2017
CompletionActual
Jun 15, 2017
Results first posted
Aug 2, 2018
Last update
Aug 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02558894
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 24, 2015
Start date
Nov 16, 2015
Primary completion
Jun 15, 2017
Completion
Jun 15, 2017
Results posted
Aug 2, 2018
Last update
Aug 2, 2018

Study contacts

Eileen M O'Reilly, M.D
principal investigator · Memorial Sloan Kettering Cancer Center, 300 East 66th Street,New York,NY 10065

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion